Sage Therapeutics Leadership

Jeffrey Jonas joined SAGE Therapeutics as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Dr. Jonas served as the President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Dr. Jonas founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards. Dr. Jonas received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard, and then served as Chief Resident in psychopharmacology at McClean Hospital, Harvard Medical School.

Al Robichaud is a Chief Scientific Officer at SAGE Therapeutics.

Barry E. Greene assumed the role of CEO at Sage Therapeutics on December 15th, 2020.

Barry joined the Sage Board of Directors in October 2020 and brings over 30 year of experience to this position. He most recently served as President of Alnylam Pharmaceuticals, Inc., since 2007 and he previously held the position of Chief Operating Officer when he first joined the company in 2003. Prior to his 17 year tenure at Alnylam, Mr. Greene was the General Manager of Oncology at Millennium Pharmaceuticals, Inc where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE® (bortezomib) in mid-2003. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company. Earlier in Barry’s career, he held such leadership positions as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and as a partner of Andersen Consulting, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice.

Barry has served as a member of the boards of directors of Karyopharm Therapeutics, Inc., since 2013, and Acorda Therapeutics, Inc., since 2007, where he also serves as a member of the compensation committee. He received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Fuqua School of Business.

Kimi Iguchi joined SAGE Therapeutics in March 2013 as Chief Financial Officer with more than 15 years of progressive experience managing finance, accounting, operations and human resources in emerging life science companies. Prior to joining SAGE, Ms. Iguchi has led the organizational development of strategic business plans, portfolio management, deal structure, fund raising, financial planning, and operations infrastructure design and growth. She has held positions at Warp Drive Bio, LLC, Santhera Pharmaceuticals, Cyberkinetics, Millennium Pharmaceuticals and Biogen, Inc. She began her career at PricewaterhouseCoopers LLP, Boston. Ms. Iguchi holds a B.A. in chemistry from Drew University, received her MBA from Northeastern University, and earned her CPA in Massachusetts.

Jeffrey Jonas joined SAGE Therapeutics as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Dr. Jonas served as the President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Dr. Jonas founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards. Dr. Jonas received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard, and then served as Chief Resident in psychopharmacology at McClean Hospital, Harvard Medical School.

Al Robichaud is a Chief Scientific Officer at SAGE Therapeutics.

Barry E. Greene assumed the role of CEO at Sage Therapeutics on December 15th, 2020.

Barry joined the Sage Board of Directors in October 2020 and brings over 30 year of experience to this position. He most recently served as President of Alnylam Pharmaceuticals, Inc., since 2007 and he previously held the position of Chief Operating Officer when he first joined the company in 2003. Prior to his 17 year tenure at Alnylam, Mr. Greene was the General Manager of Oncology at Millennium Pharmaceuticals, Inc where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE® (bortezomib) in mid-2003. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company. Earlier in Barry’s career, he held such leadership positions as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and as a partner of Andersen Consulting, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice.

Barry has served as a member of the boards of directors of Karyopharm Therapeutics, Inc., since 2013, and Acorda Therapeutics, Inc., since 2007, where he also serves as a member of the compensation committee. He received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Fuqua School of Business.